BriaCell Therapeutics (NASDAQ:BCTX) Releases Quarterly Earnings Results, Beats Estimates By $0.45 EPS

BriaCell Therapeutics (NASDAQ:BCTX) announced its quarterly earnings data on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.45, Yahoo Finance reports.

BriaCell Therapeutics Trading Down 7.5 %

Shares of NASDAQ BCTX traded down $0.06 during mid-day trading on Wednesday, reaching $0.77. The company had a trading volume of 1,056,385 shares, compared to its average volume of 1,639,271. The firm has a 50 day simple moving average of $0.80 and a two-hundred day simple moving average of $1.15. The stock has a market cap of $27.59 million, a P/E ratio of -0.66 and a beta of 1.34. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $5.97.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a report on Thursday, October 3rd.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.